Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 26, 2013

View Archived Issues

D-Pharm begins phase II study of DP-b99 in high-risk pancreatitis

Regulus Therapeutics provides update on biomarker collaboration with Biogen Idec

New test for predicting response to cancer therapy launched by Serametrix

Trial shows promising results for SAPPHIRE II eye test designed to identify AD

Lpath focuses on new antibody program targeting respiratory disease

PF-06463922, a novel small molecule for the treatment of cancer

Taiho presents data on two SYK inhibitors for DLBCL

Demonstration of the antitumor efficacy of a novel kinase inhibitor for breast and prostate cancer

Novel apoptotic agent induces cell death in lung tumors

First-in-human results support proof of mechanism for MAO-B inhibition by YKP-10461

Eisai to receive marketing authorization holder license for Gliadel in Japan

CCX-650 leads to significantly prolonged survival in animal models of glioblastoma

GlaxoSmithKline patents new MCH1 receptor antagonists

Novel PKC-beta inhibitors synthesized at Sanofi

Bayer Schering Pharma designs new BUB1 inhibitors

Ariad Pharmaceuticals obtains positive CHMP opinion on the continued use of Iclusig

TG Therapeutics begins first combination trial of TG-1101 and TGR-1202

Andexanet alfa receives FDA breakthrough therapy designation

Santen launches Alesion ophthalmic solution in Japan

FDA grants priority review status to NDA for corneal cross-linking system

Celgene receives positive CHMP opinion for Abraxane in combination with gemcitabine

Cubist reports topline results from pivotal trial of ceftolozane/tazobactam in cUTIs

FDA grants fast track designation to Cerecor's CERC-301 for major depressive disorder

Anafranil approved for new indication in Japan

Preclinical findings suggest diminished abuse potential for MG-01CI

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 18, 2025.
An early stage 85% remissions rate in AML drives Aptevo’s stock surge
BioWorld
An 85% remissions rate was found in updated results from Aptevo Therapeutics Inc.’s ongoing phase Ib/II Ranier study of mipletamig in one of the toughest blood...
BIO 2025: Makary lays out FDA’s path, launches pilot review program
BioWorld
On the same day that FDA Commissioner Martin Makary spoke in a fireside chat during the 2025 Biotechnology Innovation Organization’s International Convention, the...
Alphadesign: AI creating proteins from scratch
BioWorld Science
The Alphafold machine learning system for predicting a protein’s structure from its amino acid sequence has been adapted to make it possible to design de novo...